Invesco Ltd. Xeris Biopharma Holdings, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 67,666 shares of XERS stock, worth $197,584. This represents 0.0% of its overall portfolio holdings.

Number of Shares

67,666

Previous 66,529 1.71%

Holding current value

$197,584

Previous $149,000 28.86%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$2.06 - $2.96 $2,342 - $3,365	1,137 Added 1.71%	67,666 $192,000
Q2 2024 Aug 13, 2024	BUY	$1.7 - $2.45 $4,635 - $6,681	2,727 Added 4.27%	66,529 $149,000
Q1 2024 May 14, 2024	BUY	$2.04 - $3.22 $1,275 - $2,012	625 Added 0.99%	63,802 $141,000
Q4 2023 Feb 12, 2024	SELL	$1.47 - $2.36 $377,012 - $605,271	-256,471 Reduced 80.24%	63,177 $148,000
Q3 2023 Nov 13, 2023	SELL	$1.8 - $2.69 $3.21 Million - $4.8 Million	-1,784,974 Reduced 84.81%	319,648 $594,000
Q2 2023 Aug 11, 2023	BUY	$1.82 - $2.98 $4,158 - $6,809	2,285 Added 0.11%	2,104,622 $5.51 Million
Q1 2023 May 12, 2023	BUY	$1.03 - $1.63 $2,344 - $3,709	2,276 Added 0.11%	2,102,337 $3.43 Million
Q4 2022 Feb 13, 2023	SELL	$1.14 - $1.65 $7,973 - $11,540	-6,994 Reduced 0.33%	2,100,061 $2.79 Million
Q3 2022 Nov 14, 2022	BUY	$1.37 - $1.93 $9,383 - $13,218	6,849 Added 0.33%	2,107,055 $3.29 Million
Q2 2022 Aug 15, 2022	BUY	$1.48 - $2.64 $92,967 - $165,834	62,816 Added 3.08%	2,100,206 $3.23 Million
Q1 2022 May 16, 2022	BUY	$2.0 - $2.87 $2,528 - $3,627	1,264 Added 0.06%	2,037,390 $5.22 Million
Q4 2021 Feb 14, 2022	BUY	$1.8 - $2.93 $3.67 Million - $5.97 Million	2,036,126 New	2,036,126 $5.97 Million

Others Institutions Holding XERS

# of Institutions

141

Shares Held

59.9M

Call Options Held

148K

Put Options Held

45.7K

View Full List

About Xeris Biopharma Holdings, Inc.

Ticker XERS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 135,956,992
Market Cap $397M
Description
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...

More about XERS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account